Log in to post a reply
Jan 26, 2022 08:23AM margun wrote:
I had herceptin. I have no success registering it in my profile.
According to the table, after 5 years the recurrence is only 2 percent for early stagers
Posted on: Nov 3, 2014 08:47AM
Posted on: Nov 3, 2014 08:47AM
Lovemyboysandlabs wrote:
Hello, I was dx in February with Her2+ BC. I went through the chemo, the mastectomy and now in the midst of radiation. I will finish that in December and will be on the Herceptin through March.
I, like so many BC survivors, have a constant fear of metastisis. I can't shake it. I think what I need is to read stories of those with my type of BC that have survived for years with no recurrence. Please share your stories with those of us that are still in treatment or just finishing that are scared.
Thanks!
Jan 26, 2022 08:23AM margun wrote:
I had herceptin. I have no success registering it in my profile.
According to the table, after 5 years the recurrence is only 2 percent for early stagers
Jan 26, 2022 09:32AM beesie.is.out-of-office wrote:
I'm not HER2+ but I saw this discussion in the Active List and thought that I'd pop in and add this graph. It's important to note that this wasn't a large study but it does address the recent questions in terms of risk of recurrence after 5 years for HER2+ patients.
Source: https://wjso.biomedcentral.com/articles/10.1186/s1...
Jan 26, 2022 09:55AM mcbaker wrote:
Yes, small sample, and no breakdown of what stage de novo.
Jan 26, 2022 11:47AM specialk wrote:
Just wanted to add that the general consensus is that Her2+ driven recurrence usually happens in the first 2-3 years post treatment, if those with recurrence are years out it is possibly more likely to be driven by the hormonal aspect. I think this study has good generalized info, but there are several things to note. This study was looking at patients from 2005-2013. It appears that in the text between Table 4 and Fig 1, 92% of the Her2+ patients did not receive adjuvent Herceptin. Since this study was looking at a timeframe earlier than 2013, Perjeta would not have been prescribed yet and neoadjuvent systemic treatment was unlikely. Kadcyla for residual disease in larger tumors, node positives, or high risk patients would certainly not have been given. The unfortunate thing about studies is that they are often looking at data collected earlier than the use of current treatment regimens that have now become standard of care, so there is some degree of lag. As is pointed out at the end of the discussion in the study, if you are having any treatment that is different from what was studied it makes it a bit harder to apply these stats to those being treated now or in the recent past. In a subtype like Her2+ disease, that has a rapidly changing treatment environment, it can be a challenge to interpret and apply info!
Jan 26, 2022 12:34PM - edited Jan 26, 2022 12:46PM by DeniseML
Thank-you Raliegh girl for your post. it is up-lifting and encouraging to hear your story since I, too had IDC, 2 large tumors - 6 cm. combined, many, many lymph nodes involved, ER- HER2+, same chemo and targeted therapy with pCR. I did have inflammatory BC also. I am 18 months out of initial diagnosis and 7 months out from end of all treatment.
I thought I had read something about highest risk for our scenario was first 5 years, first 2 being the highest incidents of recurrence. I try not to dwell on risks .
wishing all the best of luck and happiest life has to offer!
Mar 10, 2022 01:28AM spudsie wrote:
HER2 3C on diagnosis Aug 2015, (12/36 nodes positive and removed) Double Mastectomy in Oct 2015. This was followed with Chemo + Herceptin. Didn't go through with radiotherapy. Implants in at the mastectomy. Had them out 6 months later. I hated them. It's been 6 1/2 years now. I honestly don't even really think about it until a mate gets Breast cancer and wants to talk about their options.
Mar 10, 2022 12:10PM moth wrote:
"HER2-positive breast cancer progressively turned from the most feared to the most curable subtype.
Currently, more than 9 out of 10 patients with HER2-positive breast cancer who are treated with chemotherapy and HER2-blockade are free from recurrence 6 years after surgery.3 The treatment and outcomes of HER2-positive breast cancer have improved so much that the research focus has gradually shifted from treatment escalation toward a search for safe de-escalation opportunities."
More Tolerable Cures for Patients With Early-Stage HER2-Positive Breast Cancer: Halfway to Precision March 2022
https://dailynews.ascopubs.org/do/10.1200/ADN.22.2...
Initial dx at 50. Seriously?? “Sometimes the future changes quickly and completely and we’re left with only the choice of what to do next." blog: Never Tell Me the Odds
Dx 12/2017, IDC, Left, 1cm, Stage IA, Grade 3, 0/5 nodes, ER-/PR-, HER2- Surgery 12/12/2017 Lumpectomy; Lumpectomy (Left); Lymph node removal Chemotherapy 2/14/2018 AC + T (Taxol) Radiation Therapy 8/13/2018 Whole breast: Breast Dx 2/2020, IDC, Left, Stage IV, metastasized to liver/lungs, Grade 3, ER-/PR-, HER2- Chemotherapy 3/18/2020 Taxol (paclitaxel) Immunotherapy 3/19/2020 Tecentriq (atezolizumab) Chemotherapy 11/26/2020 Abraxane (albumin-bound or nab-paclitaxel) Radiation Therapy 12/9/2020 External Hormonal Therapy 12/16/2020 Femara (letrozole) Radiation Therapy 3/3/2021 External Local Metastases 3/3/2021 Radiation therapy: Bone Targeted Therapy 1/1/2022 Trodelvy (sacituzumab govitecan-hziy) Chemotherapy 6/1/2022 OtherMar 16, 2022 03:31PM melbo wrote:
thanks for sharing Moth! That is very heartening news, especially for hormone negative folks. Now I just wish they could make such great progress for triple negatove
